• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Increased pre-chemotherapy inflammatory biomarkers (IL-6 and CRP) correlated to increased risk of frailty post-chemotherapy in older breast cancer patients

byKassandra McFarlaneandSze Wah Samuel Chan
December 28, 2022
in Chronic Disease, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. 25.8% of patients receiving chemotherapy for breast cancer experienced worsening frailty status.

2. Patients with both biomarkers (IL-6 and CRP) elevated before chemotherapy had a significantly higher risk of decline in frailty status.

Evidence Rating Level: 2 (Good)

Study Rundown: Interleukin-6 (IL-6) and C-reactive protein (CRP) are two inflammatory biomarkers that have been associated with worse post-chemotherapy frailty in older patients diagnosed and treated for breast cancer. This study investigated whether there was worsening frailty status from baseline corresponding to inflammatory biomarkers after adjuvant chemotherapy in patients with breast cancer. Median cutoff levels were chosen based on previous studies and IL-6 was 2.5pg/mL and CRP was 3.5 mg/L. The primary outcome of this study was whether there was a post-chemotherapy decline in frailty status as measured by a Deficit Accumulation Index (DAI). In the baseline characteristics assessment, it was found that BMI or use of anti-inflammatory medication were not associated with biomarkers of inflammation (IL-6 and CRP). There was evidence of worsening frailty status in 25.8% of women as a result of chemotherapy treatment for their breast cancer. Patients who became frailer had significantly higher baseline levels of inflammatory biomarkers IL-6 and CRP. Limitations to this study include the short follow-up period which makes it difficult to apply conclusions to the long-term recovery of frailty status. Additionally, the study did not account for events that may have occurred during treatment, including hospitalizations or severe toxicities due to treatment. Overall, the results from this study reveal that high baseline levels of inflammatory biomarkers IL-6 and CRP are associated with increased frailty due to chemotherapy after treatment for breast cancer.

Click to read the study in the Journal of Clinical Oncology

Relevant Reading: Interleukin-6 and C-reactive protein, successful aging, and mortality: The PolSenior study.

RELATED REPORTS

The Scan by 2 Minute Medicine®: Celebrity diagnoses spur screenings, athlete mental-health push, reality-TV heart lesson, and a sitcom PSA wave

Breast cancer survivors may have a lower risk of Alzheimer’s dementia

Abbreviated MRI is superior to whole-breast ultrasound for detection of cancer in dense breasts

In-Depth [prospective cohort]: This prospective cohort study was completed out of 16 healthcare centres in the United States. The study enrolled adult patients who were 65 years and older and who were diagnosed and treated for stage I, II, or III breast cancer. The final study cohort was comprised of 295 patients, 37.3% of whom had stage I and 62.7% who had either stage II or III cancer. Prior to receiving chemotherapy, 82% of patients received breast cancer surgery (48% received a mastectomy and 52% received a lumpectomy). Patients who had higher baseline levels of IL-6 (median 3.57 pg/mL) experienced a decline in their frailty status after receiving chemotherapy, as compared to those who did not experience a decline (median 2.15 pg/mL). The result was similar for baseline CRP levels (median 4.75 mg/L compared to 3.06 mg/L, respectively). The majority of the 76 patients who experienced a decline in their frailty status post-chemotherapy had high levels of biomarkers; 63.2% had high CRP, 65.8% had high IL-6 and almost half (46.1%) had high levels of both biomarkers. Chemotherapy-induced frailty was 2.2 times more likely in those with high IL-6 (odds ratio (OR) 2.21; 95% confidence interval (CI), 1.28-3.80) and was 2.1 times more likely in those with high CRP (OR, 2.1; 95% CI, 1.23-3.62). Patients who had increased levels of both biomarkers had a more than 3-fold increased odds of frailty after chemotherapy (OR, 3.61; 95% CI, 1.75-7.44). There was a clinically significant median change of 0.06 in the DAI pre- and post-chemotherapy overall. When comparing with patients whose frailty status was unaffected it was found that there was a greater change in DAI in those patients whose frailty status declined (median change in DAI 0.12 vs. 0.03).

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Breast Cancerfrailtygeri-oncology
Previous Post

More permissive parameters for active surveillance eligibility is potentially possible in slow-growing thyroid cancers

Next Post

Dapagliflozin slows disease progression in patients with heart failure with preserved ejection fraction

RelatedReports

The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Celebrity diagnoses spur screenings, athlete mental-health push, reality-TV heart lesson, and a sitcom PSA wave

July 2, 2025
Chronic Disease

Breast cancer survivors may have a lower risk of Alzheimer’s dementia

July 2, 2025
3D mammography (tomosynthesis) enhances accuracy of breast cancer screening
Chronic Disease

Abbreviated MRI is superior to whole-breast ultrasound for detection of cancer in dense breasts

June 25, 2025
#VisualAbstract: Elinzanetant Effectively Reduces Vasomotor Symptoms from Endocrine Therapy for Breast Cancer
StudyGraphics

#VisualAbstract: Elinzanetant Effectively Reduces Vasomotor Symptoms from Endocrine Therapy for Breast Cancer

June 17, 2025
Next Post
Remote patient monitoring did not reduce heart failure readmissions: The BEAT-HF trial

Dapagliflozin slows disease progression in patients with heart failure with preserved ejection fraction

Quick Take: Amyotrophic Lateral Sclerosis versus Multifocal Motor Neuropathy: Utility of MR Neurography

Tofersen does not improve ALS symptoms in patients with SOD1 mutations

Factors contributing to parents providing alcohol sips to adolescents

Effectiveness of stand-alone telephone-delivered intervention for reducing problem alcohol use

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • MLC901 may be effective in treatment of post-concussion symptoms in phase III study
  • Risk of dementia increased with gabapentin prescription in back pain patients
  • New-generation antiseizure medications are better tolerated for patients with epilepsy
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.